SCHEMBL9987124

SCHEMBL9987124

COC(=O)c1cc(Cl)cc(Br)c1F

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SOS1 Q07889 1/20 0.47
ABL1 P00519 1/20 0.44
SERPINH1 P50454 1/20 0.43
PDK2 Q15119 1/20 0.42
SLC6A3 Q01959 3/20 0.41
SLC6A4 P31645 2/20 0.41
NR4A2 P43354 2/20 0.39
SIRT6 Q8N6T7 1/20 0.38
GAA P10253 1/20 0.38
NOTUM Q6P988 1/20 0.37
LMNA P02545 1/20 0.37
TSHR P16473 1/20 0.37
NPSR1 Q6W5P4 1/20 0.37
MEN1 O00255 2/20 0.36
MAPT P10636 2/20 0.36
KMT2A Q03164 2/20 0.36
EPAS1 Q99814 1/20 0.36
ALDH1A1 P00352 1/20 0.36
HPGD P15428 1/20 0.36
XBP1 P17861 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL19971599 0.82 SOS1 (0.49) SOS1PDK2SLC6A3SLC6A4NR4A2
SCHEMBL31055681 0.82 SOS1 (0.49) SOS1PDK2SLC6A3SLC6A4NR4A2
SCHEMBL5853128 0.82 SOS1 (0.49) SOS1PDK2SLC6A3SLC6A4NR4A2
SCHEMBL31636871 0.81 ABL1 (0.45) SOS1ABL1SERPINH1PDK2SLC6A3
SCHEMBL16069727 0.81 SOS1 (0.48) SOS1NR4A2GAANOTUMTSHR
SCHEMBL25308574 0.81 CA12 (0.49) SOS1PDK2NR4A2GAANOTUM
SCHEMBL21817258 0.81 SOS1 (0.48) SOS1PDK2NR4A2GAANOTUM
SCHEMBL13280552 0.81 ABL1 (0.45) SOS1ABL1SERPINH1PDK2SLC6A3
SCHEMBL3203329 0.81 ABL1 (0.45) ABL1SERPINH1PDK2SLC6A3SLC6A4
SCHEMBL31502301 0.80 SOS1 (0.54) SOS1ABL1PDK2SLC6A3SLC6A4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-119176772-A Compound with Mrgpr X receptor inhibition effect and application thereof 博济医药科技股份有限公司 2024-12-24 CN disclosed
EP-2585454-A1 HETEROARYL COMPOUNDS AND COMPOSITIONS AS PROTEIN KINASE INHIBITORS Novartis AG (CH) 2013-05-01 EP disclosed
US-20130096149-A1 HETEROARYL COMPOUNDS AND COMPOSITIONS AS PROTEIN KINASE INHIBITORS NOVARTIS AG (CH) 2013-04-18 US disclosed
WO-2011161216-A1 HETEROARYL COMPOUNDS AND COMPOSITIONS AS PROTEIN KINASE INHIBITORS NOVARTIS AG (CH) 2011-12-29 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20130096149-A1 HETEROARYL COMPOUNDS AND COMPOSITIONS AS PROTEIN KINASE INHIBITORS BRAF, RAF1, ARAF SOS1 1771/4885ABL1 23/4885SERPINH1 2238/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.